Gelteq Limited Ordinary SharesNASDAQ: GELS

Profile

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

Australia

IPO:

Website:

http://www.gelteq.com

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A

Market cap

$14.25 M
-48%vs. 3y high
21%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

1.35
-48%vs. 3y high
46%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$1.51-$0.10(-6.21%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

--

Revenue

Revenue target

--

Revenue

Net income

--

Analysts recommendations

Total assets

Total liabilities

$13.83 M$3.24 M

Institutional Ownership

Included in screeners

No data

Similar companies

NRx Pharmaceuticals logo

NRx Pharmaceuticals (NRXP)

China Jo-Jo Drugstores logo

China Jo-Jo Drugstores (CJJD)

TRxADE HEALTH logo

TRxADE HEALTH (MEDS)

Psychemedics logo

Psychemedics (PMD)

Minerva Neurosciences logo

Minerva Neurosciences (NERV)

Cumberland Pharmaceuticals logo

Cumberland Pharmaceuticals (CPIX)

Vivos Therapeutics logo

Vivos Therapeutics (VVOS)

Autonomix Medical Common Stock logo

Autonomix Medical Common Stock (AMIX)

GELS Latest News

Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
globenewswire.com12 November 2024 Sentiment: POSITIVE

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.

Gelteq Limited Closes US$5.2 Million Initial Public Offering
globenewswire.com30 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The ordinary shares commenced trading on the Nasdaq Global Market on October 29, 2024 under the symbol “GELS.”

What type of business is Gelteq Limited Ordinary Shares?

Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.

What sector is Gelteq Limited Ordinary Shares in?

Gelteq Limited Ordinary Shares is in the Healthcare sector

What industry is Gelteq Limited Ordinary Shares in?

Gelteq Limited Ordinary Shares is in the Drug Manufacturers - Specialty & Generic industry

What country is Gelteq Limited Ordinary Shares from?

Gelteq Limited Ordinary Shares is headquartered in Australia

What is Gelteq Limited Ordinary Shares website?

https://www.gelteq.com

Is Gelteq Limited Ordinary Shares in the S&P 500?

No, Gelteq Limited Ordinary Shares is not included in the S&P 500 index

Is Gelteq Limited Ordinary Shares in the NASDAQ 100?

No, Gelteq Limited Ordinary Shares is not included in the NASDAQ 100 index

Is Gelteq Limited Ordinary Shares in the Dow Jones?

No, Gelteq Limited Ordinary Shares is not included in the Dow Jones index

When was Gelteq Limited Ordinary Shares the previous earnings report?

No data

When does Gelteq Limited Ordinary Shares earnings report?

Next earnings report date is not announced yet